Last reviewed · How we verify
Dexamethasone+NK-1 RA+5-HT3 RA
Dexamethasone+NK-1 RA+5-HT3 RA is a Antiemetic combination therapy Small molecule drug developed by Fifth Affiliated Hospital, Sun Yat-Sen University. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Also known as: Acidocont, Deronil, Dexacortal, Desameton.
This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism.
This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | Dexamethasone+NK-1 RA+5-HT3 RA |
|---|---|
| Also known as | Acidocont, Deronil, Dexacortal, Desameton, Fluprednisolone |
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Antiemetic combination therapy |
| Target | Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology (supportive care) |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone is a glucocorticoid that reduces inflammation and CINV through multiple pathways. NK-1 receptor antagonists block substance P signaling in the chemoreceptor trigger zone and vomiting center. 5-HT3 receptor antagonists (ondansetron-class agents) block serotonin signaling at peripheral and central sites. Together, these three mechanisms target complementary pathways to prevent acute and delayed CINV in patients receiving highly emetogenic chemotherapy.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Dizziness
- Hyperglycemia (dexamethasone-related)
- Insomnia
Key clinical trials
- NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens (PHASE3)
- Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone+NK-1 RA+5-HT3 RA CI brief — competitive landscape report
- Dexamethasone+NK-1 RA+5-HT3 RA updates RSS · CI watch RSS
- Fifth Affiliated Hospital, Sun Yat-Sen University portfolio CI
Frequently asked questions about Dexamethasone+NK-1 RA+5-HT3 RA
What is Dexamethasone+NK-1 RA+5-HT3 RA?
How does Dexamethasone+NK-1 RA+5-HT3 RA work?
What is Dexamethasone+NK-1 RA+5-HT3 RA used for?
Who makes Dexamethasone+NK-1 RA+5-HT3 RA?
Is Dexamethasone+NK-1 RA+5-HT3 RA also known as anything else?
What drug class is Dexamethasone+NK-1 RA+5-HT3 RA in?
What development phase is Dexamethasone+NK-1 RA+5-HT3 RA in?
What are the side effects of Dexamethasone+NK-1 RA+5-HT3 RA?
What does Dexamethasone+NK-1 RA+5-HT3 RA target?
Related
- Drug class: All Antiemetic combination therapy drugs
- Target: All drugs targeting Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor
- Manufacturer: Fifth Affiliated Hospital, Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology (supportive care)
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
- Also known as: Acidocont, Deronil, Dexacortal, Desameton, Fluprednisolone
- Compare: Dexamethasone+NK-1 RA+5-HT3 RA vs similar drugs
- Pricing: Dexamethasone+NK-1 RA+5-HT3 RA cost, discount & access